Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Plasma intact fibroblast growth factor 23 levels in women with anorexia nervosa.

Otani M, Takimoto Y, Moriya J, Yoshiuchi K, Akabayashi A.

Biopsychosoc Med. 2008 Apr 16;2:10. doi: 10.1186/1751-0759-2-10.

2.

Plasma intact fibroblast growth factor 23 levels in women with bulimia nervosa: A cross-sectional pilot study.

Otani M, Takimoto Y, Moriya J, Yoshiuchi K, Akabayashi A.

Biopsychosoc Med. 2011 Jun 17;5:7. doi: 10.1186/1751-0759-5-7.

3.
4.

Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?

Bożentowicz-Wikarek M, Kocełak P, Owczarek A, Olszanecka-Glinianowicz M, Mossakowska M, Skalska A, Więcek A, Chudek J.

Clin Biochem. 2015 Apr;48(6):431-6. doi: 10.1016/j.clinbiochem.2014.12.027. Epub 2015 Jan 9.

PMID:
25583093
5.

Fibroblast growth factor 23 and Klotho serum levels in healthy children.

Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D.

Bone. 2014 Sep;66:8-14. doi: 10.1016/j.bone.2014.05.012. Epub 2014 May 29.

PMID:
24880094
6.

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

Wolf M, Koch TA, Bregman DB.

J Bone Miner Res. 2013 Aug;28(8):1793-803. doi: 10.1002/jbmr.1923.

7.

High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.

Igaki JM, Yamada M, Yamazaki Y, Koto S, Izawa M, Ariyasu D, Suzuki E, Hasegawa H, Hasegawa Y.

Endocr J. 2011;58(8):647-55. Epub 2011 May 19.

8.

Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men.

Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E.

Kidney Int. 2006 Dec;70(12):2141-7. Epub 2006 Oct 25.

9.

Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.

Taylor EN, Hoofnagle AN, Curhan GC.

Clin J Am Soc Nephrol. 2015 Apr 7;10(4):667-75. doi: 10.2215/CJN.07060714. Epub 2015 Jan 26.

10.

Plasma concentrations of vitamin D metabolites in pubertal girls with anorexia nervosa.

Aarskog D, Aksnes L, Markestad T, Trygstad O.

Acta Endocrinol Suppl (Copenh). 1986;279:458-67.

PMID:
3490728
12.

Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.

Vervloet MG, van Ittersum FJ, Büttler RM, Heijboer AC, Blankenstein MA, ter Wee PM.

Clin J Am Soc Nephrol. 2011 Feb;6(2):383-9. doi: 10.2215/CJN.04730510. Epub 2010 Oct 28.

13.

Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4.

Gattineni J, Alphonse P, Zhang Q, Mathews N, Bates CM, Baum M.

Am J Physiol Renal Physiol. 2014 Feb 1;306(3):F351-8. doi: 10.1152/ajprenal.00232.2013. Epub 2013 Nov 20.

14.

The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children.

Efthymiadou A, Kritikou D, Mantagos S, Chrysis D.

Eur J Endocrinol. 2016 Apr;174(4):473-9. doi: 10.1530/EJE-15-1018. Epub 2016 Jan 13.

PMID:
26764419
15.

Biological variability of plasma intact and C-terminal FGF23 measurements.

Smith ER, Cai MM, McMahon LP, Holt SG.

J Clin Endocrinol Metab. 2012 Sep;97(9):3357-65. doi: 10.1210/jc.2012-1811. Epub 2012 Jun 11.

PMID:
22689697
17.

Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD.

Stubbs JR, Zhang S, Friedman PA, Nolin TD.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1965-73. doi: 10.2215/CJN.03130314. Epub 2014 Sep 2.

18.

Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis.

Domrongkitchaiporn S, Disthabanchong S, Cheawchanthanakij R, Niticharoenpong K, Stitchantrakul W, Charoenphandhu N, Krishnamra N.

Exp Clin Endocrinol Diabetes. 2010 Feb;118(2):105-12. doi: 10.1055/s-0029-1202791. Epub 2009 May 15.

PMID:
19449283
19.

Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.

Devlin RD, Gutteridge DH, Prince RL, Retallack RW, Worth GK.

J Bone Miner Res. 1990 Nov;5(11):1121-6.

PMID:
2125401
20.

Phosphate control in reducing FGF23 levels in hemodialysis patients.

Rodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, Pendon-Ruiz de Mier MV, Agüera ML, Muñoz-Castañeda JR, Soriano S, Caravaca F, Alvarez-Lara MA, Felsenfeld A, Aljama P, Rodriguez M.

PLoS One. 2018 Aug 7;13(8):e0201537. doi: 10.1371/journal.pone.0201537. eCollection 2018.

Supplemental Content

Support Center